{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-004486","form_type":"8-K","ticker":"ODYY","cik":"0001626644","company_name":"Odyssey Health, Inc.","filed_at":"2023-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.724581+00:00","generated_at":"2026-06-13T15:32:35.086523+00:00","sec_items":["8.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Odyssey Health signs non-binding LOI to merge with Speranza Therapeutics in all-stock deal","bullets":["Speranza's lead product ST Genesis is a wearable device for opioid withdrawal, FDA cleared, 93% response rate, targets $1.4B market.","Transaction makes Speranza a wholly owned subsidiary of Odyssey; Speranza management to remain post-closing.","Merger subject to due diligence, financing, and other conditions; deal terms were not disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-004486","json":"https://secwatch.observer/filing/0001683168-23-004486.json","markdown":"https://secwatch.observer/filing/0001683168-23-004486.md","text":"https://secwatch.observer/filing/0001683168-23-004486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626644/000168316823004486/0001683168-23-004486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626644/000168316823004486/odyssey_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T15:32:35.086523+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}